Form4insider filings, from the source

SEC Form 4 · accession 0001214659-26-009594

Alzamend Neuro, Inc. · ALZN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Jul 31, 2026
Accepted (ET)
Aug 4, 2026 · 9:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001677077

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series D Convertible Preferred StockF4,F1,F2,F3—Jul 31, 2026A7,500AJul 31, 2026—Common Stock—7,500I
Common Stock Purchase WarrantsF4$4,050.00holding———Apr 26, 2022Apr 26, 2027Common Stock988988I
Common Stock Purchase WarrantsF4$108.00holding———Aug 1, 2024Aug 1, 2029Common Stock13,55613,556I
Common Stock Purchase WarrantsF4$108.00holding———Sep 27, 2024Sep 27, 2029Common Stock8,6678,667I
Common Stock Purchase WarrantsF4$108.00holding———Oct 30, 2024Oct 30, 2029Common Stock1,1111,111I
Stock Options (Right to Buy)F5$2.33holding————Nov 12, 2035Common Stock100,000100,000D

Explanation of responses

Remarks

Mr. Ault, the Executive Chairman of HSD, which wholly owns ACG, which in turn wholly owns Ault Lending, is a director of the Issuer. For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending may be deemed a director by deputization by virtue of their respective representation on the Board of Directors of the Issuer.